 | This article contains content that is written like an advertisement .(February 2024) |
Calvin Ralph Stiller (born February 12, 1941) [1] is a Canadian physician, scientist, and entrepreneur. He retired as a member of the Schulich School of Medicine & Dentistry at Western University in London, Ontario.[ citation needed ]
 |
Stiller is from Naicam, Saskatchewan. He was the third of five children born to Reverend Hilmer Stiller, a minister ordained by the Pentecostal Assemblies of Canada, and his wife Mildred (née Parsons). Stiller spent his childhood years in Naicam; later, the family would move to Tisdale, and then finally in 1947 to Saskatoon. Stiller graduated from Bedford Road Collegiate, followed by two years of undergraduate pre-medical studies in Arts and Science at the University of Saskatchewan. In 1961, Stiller entered the medical faculty at the University of Saskatchewan.
| |
Following the completion of his MD degree in 1965, Stiller pursued five years of post-graduate fellowship studies at what was then called the University of Western Ontario in London, Ont., followed by a year spent at the University of Alberta in Edmonton. Stiller developed a specialization in nephrology, as well as in the related areas of transplantation, immunology, and infection. Returning to Western in 1971, and having gained by then his fellowship designation of FRCP(C), he embarked on a long tenure at University Hospital, London. Beginning in 1972, he was appointed Chief of Nephrology and Transplantation, and later, Director of Immunology at the John P. Robarts Institute.
From the early 1970s through to the first decade of the twenty-first century, Stiller would make many contributions to his work, research, advocacy, and medical-based entrepreneurship. Additionally, Stiller had found the time to be an early adopter of computerized patient records, as well as to co-create a telephone-based medical service, which he would make public. This service became the first form of Telemedicine offered by the Government of Ontario. These foundational years of his career were very important at shaping his reputation in the medical community. The eventual widespread success of organ transplantation led to Stiller's establishing the Multi-Organ Transplant Service and the Canadian Centre for Transplantation in London, over which he acted as chief from 1984 until 1996. Organ rejection was (and remains) a major challenge in the field and Stiller was principal investigator in the early 1980s in the clinical trials and market development of the drug Cyclosporine for use as a first-line therapy for transplant rejection. In 1990, he published Lifegifts: The Real Story of Organ Transplantation, in which he, along with his brother, the Reverend Brian Stiller, recounts the history of human organ transplants. Stiller was on a team of researchers that proved in 1984 that human Type I diabetes was an autoimmune disorder and therefore amenable to a regime of immunosuppressant or immunomodulant treatment.
At the same time that Stiller was carrying out his hospital and laboratory work, he was helping also to enlarge steadily the capacity for advanced medical research and development in Canada. Stiller founded the Canadian Medical Discoveries Fund, the largest venture capital fund in Canadian medical history, which, since its inception, has raised and managed over half a billion dollars in assets. Stiller served as founder and chair of the Ontario Institute for Cancer Research, as well as the chair of Genome Canada. Along with Dr. John Evans, a former president of the University of Toronto, and Ken Knox, Stiller catalyzed the founding of the Medical and Related Science (MaRS) Discovery District in downtown Toronto, and then served as its director. It launched in 2000, and was created to bring publicly funded medical and related sciences research to Canadian and global markets. Stiller was invited by the then Premier of Ontario, Mike Harris, to chair the Ontario Research and Development Challenge Fund, which, together with the Ontario Innovation Trust, would provide over $1.2-billion in R&D support during the following decade to Ontario universities in an alliance with research-intensive businesses.
Stiller was named Ontario Entrepreneur of the Year in 1996.[ citation needed ] In 1999, Western University established the Novartis/Calvin Stiller Chair in Xenotransplantation.[ citation needed ] The next year, he was named a Member of the Order of Ontario, to go along with having been made a member of the Order of Canada a few years earlier.[ citation needed ] In 2002, the namesake Stiller Centre for Technology Commercialization was opened in London.[ citation needed ] He was recognized by his alma mater, the University of Saskatchewan, in its "100 Graduates of Influence", an all-time list celebrated to mark the university's centenary in 2007. [2]
In 2010, Stiller was inducted into the Canadian Medical Hall of Fame. [1] Also in 2010, he was made a Distinguished Fellow of the Canadian Academy of Health Sciences, [3] and won the highly prestigious Canada Gairdner Wightman Award. [4]
George Davis Snell NAS was an American mouse geneticist and basic transplant immunologist.
James Edgar Till is a University of Toronto biophysicist, best known for demonstrating – with Ernest McCulloch – the existence of stem cells.
Jacques Francis Albert Pierre Miller AC FRS FAA is a French-Australian research scientist. He is known for having discovered the function of the thymus and for the identification, in mammalian species of the two major subsets of lymphocytes and their function.
Ernest Armstrong McCulloch was a University of Toronto cellular biologist, best known for demonstrating – with James Till – the existence of stem cells.
Tak Wah Mak, is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics.
Raymond O. Heimbecker, was a Canadian cardiovascular surgeon who performed the world’s first complete heart valve transplant in 1962, and Canada’s first modern heart transplant in 1981 with anti-rejection drugs to prolong the patient's survival.
Sir Michael Francis Addison Woodruff, was an English surgeon and scientist principally remembered for his research into organ transplantation. Though born in London, Woodruff spent his youth in Australia, where he earned degrees in electrical engineering and medicine. Having completed his studies shortly after the outbreak of World War II, he joined the Australian Army Medical Corps, but was soon captured by Japanese forces and imprisoned in the Changi Prison Camp. While there, he devised an ingenious method of extracting nutrients from agricultural wastes to prevent malnutrition among his fellow POWs.
Lorne Allan Babiuk, is a Canadian scientist specializing in immunology, pathogenesis, virology, molecular virology, and vaccinology. He is the Vice-President of Research at the University of Alberta and the former Director of the Vaccine and Infectious Disease Organization at the University of Saskatchewan. Dr Babiuk holds the Canada Research Chair in Vaccinology and Biotechnology and is Chair of the Board for Pan-Provincial Vaccine Enterprise (PREVENT), a vaccine development company.
Robert Peter Gale is an American physician and medical researcher. He is known for research in leukemia and other bone marrow disorders.
Sir James Learmonth Gowans was a British physician and immunologist. In 1945, while studying medicine at King's College Hospital, he assisted at the liberated Bergen-Belsen concentration camp as a voluntary medical student.
Alan Bernstein is Professor Emeritus at the University of Toronto and President Emeritus of CIFAR, where he served as President and CEO from 2012 to 2022. A Distinguished Fellow at the Munk School of Global Affairs and Public Policy, he is also a Fellow and Member of the Standing Committee for Science Planning at the International Science Council (2022-2025). Bernstein is recognized as a leader in health research, science policy, mentorship and organizational leadership.
Bernd Schröppel is a German former transplant nephrologist at the Mount Sinai Medical Center and the former medical director of the kidney pancreas transplant program at the Recanati/Miller Transplantation Institute at the Mount Sinai Medical Center in New York City. He is also a former assistant professor of nephrology at the Mount Sinai School of Medicine.
Michael R. Hayden, is a Killam Professor of Medical Genetics at the University of British Columbia, the highest honour UBC can confer on any faculty member. Only four such awards have ever been conferred in the Faculty of Medicine. Dr. Hayden is also Canada Research Chair in Human Genetics and Molecular Medicine. Hayden is best known for his research in Huntington disease (HD).
Elizabeth Simpson OBE FRS FMedSci is a British biologist. She is the Emeritus Professor of Transplantation Biology at Imperial College London. Simpson is particularly known for her elucidation of the nature of male-associated minor transplantation antigens, and their roles in the generation of immunological tolerance, graft versus host disease, and transplant rejection.
John Herbert Dirks is a Canadian physician.
Kim Solez is an American pathologist and co-founder of the Banff Classification, the first standardized international classification for renal allograft biopsies. He is also the founder of the Banff Foundation for Allograft Pathology.
Thalachallour Mohanakumar is an Indian academic and professor with a research interest in tumor immunology for lung/breast cancer and bone marrow transplantation. His academic title is the Jacqueline G. and William E. Maritz professor of surgery, Pathology, and Immunology in the Department of Surgery at Washington University School of Medicine.
Jean-François Borel is a Belgian microbiologist and immunologist who is considered one of the discoverers of cyclosporin.
Minnie M. Sarwal is an adult and pediatric nephrologist, researcher of transplant immunology, and biotechnology entrepreneur in San Francisco. She has made significant contributions to the field of organ transplantation, including conducting the first successful complete steroid avoidance trial in the US and the first dosing safety trial for Rituximab in pediatric renal transplantation. She also spearheaded genomic and proteomics investigations into mechanisms of organ transplant injury and was the first to determine that there was substantive molecular heterogeneity in acute kidney transplant rejection. She has successfully commercialized blood testing for early diagnosis of both acute rejection and operational tolerance in kidney transplant patients, providing tools for proactive and predictive immunosuppression monitoring for transplant recipients.
Lisa Robinson is a clinician-scientist. She is a University of Toronto professor in the Department of Paediatrics and the Dean of the Temerty Faculty of Medicine, former Head of the Division of Nephrology at The Hospital for Sick Children, a Senior Scientist at the SickKids Research Institute, President American Pediatric Society 2022-2023, and the first-ever Chief Diversity officer for the Faculty of Medicine at University of Toronto.
   | This biography related to medicine in Canada is a stub. You can help Wikipedia by expanding it. |
